Results from the multinational, pivotal phase III SUNLIGHT* clinical trial of Lonsurf (trifluridine/tipiracil), alone or in combination with bevacizumab, in refractory metastatic colorectal cancer (mCRC) showed a statistically significant and clinically meaningful improvements in overall survival and progression-free survival for patients with refractory mCRC following disease progression or intolerance on two prior chemotherapy regimens compared to trifluridine/tipiracil alone.
The incidence of multiple cancer types in people under the age of 50 has been rising, with early-onset cancers now contributing to nearly 15,000 excess cases of cancer in the U.S. annually.
